Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.32 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039002 | 0.91 | ESR1 (0.33) | FAAHESR1SLC6A5HDAC1HDAC8 | |
| SCHEMBL5035391 | 0.89 | ESR1 (0.38) | FAAHESR1HDAC1HDAC8NPC1 | |
| SCHEMBL5038605 | 0.88 | ESR1 (0.39) | FAAHESR1HDAC1HDAC8NPC1 | |
| SCHEMBL5039085 | 0.84 | TP53 (0.45) | ESR1AURKARPS6KB1AURKBNPC1 | |
| SCHEMBL5039009 | 0.82 | MAOB (0.41) | ESR1HDAC1HDAC8NPC1ALDH1A1 | |
| SCHEMBL5038135 | 0.81 | LSS (0.38) | ESR1 | |
| SCHEMBL7145268 | 0.81 | TRPV3 (0.35) | FAAHESR1 | |
| SCHEMBL7152282 | 0.80 | MAPT (0.40) | ESR1NPC1ALDH1A1GAA | |
| SCHEMBL5045382 | 0.80 | LSS (0.36) | ESR1 | |
| SCHEMBL27542429 | 0.79 | ESR1 (0.38) | ESR1NPC1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449483-B2 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | AEBI JOHANNES | 2007-05-03 | — | — | US | disclosed |
| US-7173043-B2 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | AEBI JOHANNES | 2005-12-01 | — | — | US | disclosed |
| US-6951879-B2 | Substituted benzo(b)thiophenes or benzoisothiazoles which inhibit 2,3-oxidosqualene-lanosterol cyclase which is required for the biosynthesis of cholesterol, ergosterol and other sterols | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1334094-B1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| EP-1334094-A1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-13 | — | — | EP | disclosed |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. | 2002-07-04 | — | — | US | disclosed |
| WO-2002036584-A1 | CHOLESTEROL LOWERING BENZO`B! THIOPHENES AND BENZO`D! ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | LSS, CYP51A1, CYP46A1 | FAAH 3096/4885ESR1 2592/4885SLC6A5 3155/4885 |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | FAAH 4580/4885ESR1 1155/4885SLC6A5 2897/4885 |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | FAAH 4580/4885ESR1 1155/4885SLC6A5 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.